Stock Research: Collegium Pharmaceutical

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

Collegium Pharmaceutical

NasdaqGS:COLL US19459J1043
58
  • Value
    26
  • Growth
    54
  • Safety
    Safety
    54
  • Combined
    24
  • Sentiment
    84
  • 360° View
    360° View
    58
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Collegium Pharmaceutical, Inc. is a biopharmaceutical company focused on products for ADHD and moderate to severe pain. It operates in the biopharmaceutical industry, with commercial products including Jornay PM, Belbuca, Xtampza ER, Nucynta ER and Nucynta IR, and Symproic, primarily in the United States. In the last fiscal year, the company had a market cap of $1,030 million, profits of $377 million, revenue of $631 million, and 357 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 58 (better than 58% compared with alternatives), overall professional sentiment and financial characteristics for the stock Collegium Pharmaceutical are above average. The 360° View is based on consolidating four consolidated indicators, with all but one indicator above average for Collegium Pharmaceutical. The consolidated Value Rank has an attractive rank of 54, which means that the share price of Collegium Pharmaceutical is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 54% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 54, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. In addition, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 84. But the company’s financing is risky with a Safety rank of 26. This means 74% of comparable companies have a safer financing structure than Collegium Pharmaceutical. ...read more

more
Index
NASDAQ
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Nov-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
54 63 37 77
Growth
54 65 63 43
Safety
Safety
26 18 25 40
Sentiment
84 82 89 39
360° View
360° View
58 62 56 49
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
69 75 58 1
Opinions Change
86 50 50 50
Pro Holdings
n/a 88 85 100
Market Pulse
55 51 75 38
Sentiment
84 82 89 39
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
54 63 37 77
Growth
54 65 63 43
Safety Safety
26 18 25 40
Combined
24 35 22 58
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
94 96 71 100
Price vs. Earnings (P/E)
61 66 58 66
Price vs. Book (P/B)
21 23 6 44
Dividend Yield
1 1 1 1
Value
54 63 37 77
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
28 70 27 23
Profit Growth
52 100 100 98
Capital Growth
29 14 18 35
Stock Returns
88 45 77 49
Growth
54 65 63 43
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
9 12 15 36
Refinancing
39 10 27 31
Liquidity
63 61 59 71
Safety Safety
26 18 25 40

Similar Stocks

Discover high‑ranked alternatives to Collegium Pharmaceutical and broaden your portfolio horizons.

Alphabet

NasdaqGS:GOOG.L
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Cognizant Technology

NasdaqGS:CTSH
Country: USA
Industry: IT Consulting & oth. Services
Size: X-Large
Full Stock Analysis

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

CF Industries

NYSE:CF
Country: USA
Industry: Fertilizers & Agricultural Chemicals
Size: Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.